サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1443368

コレステロール低下薬の世界市場：薬剤クラス別、疾患タイプ別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測（2024～2032年）

Cholesterol-lowering Drug Market, By Drug class, By Disease type, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 288 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
コレステロール低下薬の世界市場：薬剤クラス別、疾患タイプ別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測（2024～2032年）
出版日: 2024年03月04日
発行: AnalystView Market Insights
ページ情報: 英文 288 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

世界のコレステロール低下薬の市場規模は、2023年に184億87万米ドルとなり、2024～2032年にかけてCAGR 3.4%で拡大すると予測されています。

コレステロール低下薬市場 - 市場力学

高コレステロールの悪影響に対する認識の高まりが市場需要を促進

コレステロール低下薬の世界市場は、高コレステロールの悪影響に対する認識の高まりにより、大きな成長を遂げています。この成長により、メーカー各社は患者の転帰を改善するための忍容性の高い薬剤を特定するため、大規模な治験を実施するようになりました。さらに、同分野における活発な研究開発活動が、新薬開発のためのベムペド酸の導入とともに、市場の成長に寄与しています。非スタチン使用者に対応する新薬クラスの出現が市場成長を後押ししています。しかし、スタチン使用者の増加や、様々なガイドラインによる抗高脂血症薬採用の推奨が、市場拡大をさらに後押ししています。コレステロール値の上昇は脳卒中や心筋梗塞のリスクを高める一方、高コレステロール血症は心血管疾患（CVD）や慢性腎臓病、2型糖尿病などの併存疾患に対する脆弱性の増大と関連しています。これらの要因が市場成長のさらなる促進要因となっています。ベムペド酸、PCSK9阻害剤などの治療薬のイントロダクションは、市場の継続的な拡大に寄与すると予想されます。

コレステロール低下薬市場 - 主要洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024～2032年）にCAGR 約3.4%で毎年成長すると推定されます。

薬剤クラス別では、スタチンが2023年に最大市場シェアを示すと予測されます。

疾患タイプ別では、2023年には高コレステロール血症が主要タイプでした。

地域別では、北米が2023年に収益を上げる主要市場です。

コレステロール低下薬市場 - セグメンテーション分析：

コレステロール低下薬の世界市場は、薬剤クラス別、疾患タイプ別、流通チャネル別、地域別に区分されます。

薬剤クラス別では、配合剤、PCSK9阻害剤、コレステロール吸収阻害剤、胆汁酸分泌抑制剤、スタチン系薬剤の5つに分類されます。スタチン系薬剤は、主にベムペド酸やPCSK9阻害剤などの効果的な治療薬のイントロダクションより、世界のコレステロール低下薬市場で最も大きな割合を占めています。

同市場は、疾患タイプによって4つのカテゴリーに分類されます：高コレステロール血症、心血管疾患、高脂血症、その他です。コレステロール低下薬市場の疾患タイプの中では、高コレステロール血症が圧倒的な焦点として際立っています。高コレステロール血症は、血中コレステロール値の上昇を特徴とし、心血管疾患との強い関連性からコレステロール低下薬の主要ターゲットとなっています。アテローム性動脈硬化症の主要な原因である高コレステロール血症は、心臓に関連する疾患の重大な危険因子です。そのため、製薬会社はスタチンやPCSK9阻害剤など、高コレステロール血症に対応し、心血管イベントのリスクを軽減するために特別に調整された薬剤の開発・販売に多大な投資を行っています。世界の高コレステロール血症の流行は、コレステロール低下薬の開発と市場動向を形成する上で、その優位性を強調しています。

コレステロール低下薬市場 - 地理的洞察

地理的に、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。

コレステロール低下薬市場 - 競合情勢：

コレステロール低下薬市場の各社は、進化する循環器系の健康と個別化医療の展望を戦略的にナビゲートしています。現在進行中の研究開発は、新規治療ターゲットの発見と、有効性が向上し副作用の少ない次世代コレステロール低下薬の開発に重点を置いています。ヘルスケアプロバイダー、研究機関、規制機関との戦略的な協力関係は、臨床試験の実施や新薬製剤の市場承認取得に役立っています。さらに、コレステロール管理の重要性と心血管イベントの予防におけるこれらの薬剤の役割を強調するために、教育イニシアティブや啓発キャンペーンが実施されています。市場が個別化治療アプローチにシフトする中、企業は精密医療戦略に投資し、遺伝的要因を探り、革新的な技術を活用して、個々の患者のニーズに合わせてコレステロール低下療法をカスタマイズしています。コレステロール低下薬市場は、心血管系疾患と闘い、心臓全体の健康を改善するための世界の取り組みに不可欠な存在であり続けています。

目次

第1章 コレステロール低下薬の市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 コレステロール低下薬の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 コレステロール低下薬産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 コレステロール低下薬市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 コレステロール低下薬の市場情勢

  • コレステロール低下薬市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 コレステロール低下薬市場：薬剤クラス別

  • 概要
    • セグメントシェア分析：薬剤クラス別
    • 配合剤
    • Pcsk9阻害剤
    • コレステロール吸収阻害剤
    • 胆汁酸分泌抑制剤
    • スタチン

第8章 コレステロール低下薬市場：疾患タイプ別

  • 概要
    • セグメントシェア分析：疾患タイプ別
    • 高コレステロール血症
    • 心血管疾患
    • 高脂血症
    • その他

第9章 コレステロール低下薬市場：流通チャネル別

  • 概要
    • セグメントシェア分析：流通チャネル別
    • 病院薬局
    • オンライン薬局
    • 小売薬局
    • その他

第10章 コレステロール低下薬市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：コレステロール低下薬産業

  • 競合ダッシュボード
  • 企業プロファイル
    • Daiichi Sankyo
    • Merck &Co., Inc.
    • AstraZeneca
    • Esperion Therapeutics and CJ Healthcare
    • Sanofi
    • Amgen, Inc.
    • Pfizer, Inc,
    • Merck &Co., Inc.
    • AbbVie, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • GlaxoSmithKline plc.
    • その他

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Cholesterol-lowering Drug Market: Drug class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug class
  • TABLE Global Cholesterol-lowering Drug Market, by Drug class 2019-2032 (USD Million)
  • TABLE Cholesterol-lowering Drug Market: Disease type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Disease type
  • TABLE Global Cholesterol-lowering Drug Market, by Disease type 2019-2032 (USD Million)
  • TABLE Cholesterol-lowering Drug Market: Distribution channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution channel
  • TABLE Global Cholesterol-lowering Drug Market, by Distribution channel 2019-2032 (USD Million)
  • TABLE Cholesterol-lowering Drug Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Cholesterol-lowering Drug Market, by Region 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
目次
Product Code: AVB2262

REPORT HIGHLIGHT

Cholesterol-lowering Drug Market size was valued at USD 18,400.87 Million in 2023, expanding at a CAGR of 3.4% from 2024 to 2032.

Cholesterol is categorized within the class of steroids, which are organic molecules and a type of lipids. It serves as a crucial structural component in the membranes of animal cells and is biosynthesized by all animal cells. The significance of cholesterol lies in its role in the biological synthesis of steroid hormones such as testosterone and estrogen, vitamin D, and bile acids. The primary sources of cholesterol production include poultry, meat, eggs, and dairy products. Elevated cholesterol levels can result from genetic diseases, obesity, an unhealthy diet, and various other medical conditions. The market for cholesterol-lowering drugs encompasses pharmaceuticals designed to decrease elevated cholesterol levels in the bloodstream, with a primary focus on reducing low-density lipoprotein (LDL) cholesterol. These drugs play a pivotal role in managing cardiovascular health by lowering the risk of atherosclerosis and related complications. As conditions like hypercholesterolemia and cardiovascular diseases become more prevalent globally, cholesterol-lowering drugs, such as statins, PCSK9 inhibitors, and bile acid sequestrants, are commonly prescribed to regulate cholesterol levels and mitigate the risk of heart-related conditions.

Cholesterol-lowering Drug Market- Market Dynamics

Increasing awareness of high cholesterol's adverse effects to propel market demand

The global Cholesterol-lowering Drug market is experiencing significant growth, driven by increasing awareness of high cholesterol's adverse effects. This growth has prompted manufacturers to conduct extensive investigational studies to identify well-tolerated drugs for improved patient outcomes. Furthermore, robust research and development activities in the sector, along with the incorporation of bempedoic acid for developing new drugs, contribute to the market's growth. The emergence of new drug classes catering to non-statin users is boosting market growth. However, the rising number of statin users and the endorsement of antihyperlipidemic adoption by various guidelines further propel market expansion. Elevated cholesterol levels increase the risks of stroke and myocardial infarction, while hypercholesterolemia is linked to increased vulnerability to cardiovascular diseases (CVD) and comorbidities like chronic kidney disease and type 2 diabetes. These factors act as additional drivers for market growth. The introduction of therapies such as bempedoic acid, PCSK9 inhibitors, and other drugs is expected to contribute to the market's continued expansion.

Cholesterol-lowering Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.4% over the forecast period (2024-2032)

Based on drug class segmentation, statins was predicted to show maximum market share in the year 2023

Based on disease type segmentation, hypercholesterolemia was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cholesterol-lowering Drug Market- Segmentation Analysis:

The Global Cholesterol-lowering Drug Market is segmented on the basis of Drug class, Disease type, Distribution Channel, and Region.

The market is divided into five categories based on drug class: combination drugs, PCSK9 inhibitors, cholesterol absorption inhibitors, bile acid sequestrants, and statins. The statins segment commands the largest portion of the global cholesterol-lowering drug market, primarily due to the introduction of effective therapies such as bempedoic acid and PCSK9 inhibitors.

The market is divided into four categories based on disease type: Hypercholesterolemia, Cardiovascular Diseases, Hyperlipidaemia, Others. Among the disease types in the cholesterol-lowering drug market, hypercholesterolemia stands out as a dominant focus. Hypercholesterolemia, characterized by elevated levels of cholesterol in the blood, is a primary target for cholesterol-lowering drugs due to its strong association with cardiovascular diseases. As a key contributor to atherosclerosis, hypercholesterolemia is a significant risk factor for heart-related conditions. Consequently, pharmaceutical companies are heavily invested in developing and marketing drugs, such as statins and PCSK9 inhibitors, specifically tailored to address hypercholesterolemia and mitigate the risk of cardiovascular events. The prevalence of hypercholesterolemia worldwide underscores its dominance in shaping the landscape of cholesterol-lowering drug development and market trends.

Cholesterol-lowering Drug Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Cholesterol-lowering Drug Market- Competitive Landscape:

Companies in the cholesterol-lowering drug market are strategically navigating the evolving landscape of cardiovascular health and personalized medicine. Ongoing research and development efforts focus on the discovery of novel therapeutic targets and the development of next-generation cholesterol-lowering drugs with improved efficacy and fewer side effects. Strategic collaborations with healthcare providers, research institutions, and regulatory bodies aid in conducting clinical trials and gaining market approvals for new drug formulations. Additionally, educational initiatives and awareness campaigns are undertaken to highlight the importance of cholesterol management and the role of these drugs in preventing cardiovascular events. As the market shifts towards personalized treatment approaches, companies are investing in precision medicine strategies, exploring genetic factors, and leveraging innovative technologies to tailor cholesterol-lowering therapies for individual patient needs. The cholesterol-lowering drug market remains integral to global efforts in combating cardiovascular diseases and improving overall heart health.

Recent Developments:

In 2021, Inclisiran received approval for NHS use following clinical trials that demonstrated its ability to reduce LDL cholesterol levels by approximately 50%. According to NHS England, Inclisiran, marketed under the brand name Leqvio, has the potential to avert 55,000 heart attacks and strokes, leading to an estimated 30,000 lives saved by the year 2031.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Daiichi Sankyo

Merck & Co., Inc.

AstraZeneca

Esperion Therapeutics and CJ Healthcare

Sanofi

Amgen, Inc.

Pfizer, Inc,

Merck & Co., Inc.

AbbVie, Inc.

Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Company Limited

Novartis AG

GlaxoSmithKline plc.

Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Combination drugs
  • Pcsk9 inhibitors
  • Cholesterol absorption inhibitors
  • Bile acid sequestrants
  • Statins

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hypercholesterolemia
  • Cardiovascular Diseases
  • Hyperlipidaemia
  • Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cholesterol-lowering Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cholesterol-lowering Drug Market Snippet by Drug class
    • 2.1.2. Cholesterol-lowering Drug Market Snippet by Disease type
    • 2.1.3. Cholesterol-lowering Drug Market Snippet by Distribution channel
    • 2.1.4. Cholesterol-lowering Drug Market Snippet by Country
    • 2.1.5. Cholesterol-lowering Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Cholesterol-lowering Drug Key Market Trends

  • 3.1. Cholesterol-lowering Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cholesterol-lowering Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cholesterol-lowering Drug Market Opportunities
  • 3.4. Cholesterol-lowering Drug Market Future Trends

4. Cholesterol-lowering Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cholesterol-lowering Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cholesterol-lowering Drug Market Landscape

  • 6.1. Cholesterol-lowering Drug Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cholesterol-lowering Drug Market - By Drug class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug class, 2023 & 2032 (%)
    • 7.1.2. Combination drugs
    • 7.1.3. Pcsk9 inhibitors
    • 7.1.4. Cholesterol absorption inhibitors
    • 7.1.5. Bile acid sequestrants
    • 7.1.6. Statins

8. Cholesterol-lowering Drug Market - By Disease type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease type, 2023 & 2032 (%)
    • 8.1.2. Hypercholesterolemia
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Hyperlipidaemia
    • 8.1.5. Others

9. Cholesterol-lowering Drug Market - By Distribution channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Retail Pharmacies
    • 9.1.5. Others

10. Cholesterol-lowering Drug Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Cholesterol-lowering Drug Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Cholesterol-lowering Drug Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Cholesterol-lowering Drug Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Cholesterol-lowering Drug Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Cholesterol-lowering Drug Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Cholesterol-lowering Drug Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Daiichi Sankyo
    • 11.2.2. Merck & Co., Inc.
    • 11.2.3. AstraZeneca
    • 11.2.4. Esperion Therapeutics and CJ Healthcare
    • 11.2.5. Sanofi
    • 11.2.6. Amgen, Inc.
    • 11.2.7. Pfizer, Inc,
    • 11.2.8. Merck & Co., Inc.
    • 11.2.9. AbbVie, Inc.
    • 11.2.10. Sun Pharmaceutical Industries Ltd.
    • 11.2.11. Takeda Pharmaceutical Company Limited
    • 11.2.12. Novartis AG
    • 11.2.13. GlaxoSmithKline plc.
    • 11.2.14. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us